Navigation Links
Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies
Date:1/19/2010

NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- As part of its mission to speed development of transformative treatments for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research announced a total of $2.1 million in awards to six biotech and pharmaceutical companies under its industry-exclusive Therapeutics Development Initiative (TDI). The funding will drive pre-clinical projects pushing forward investigations of promising neuroprotective therapeutic targets for Parkinson's.

Three teams will focus on strategies to address inflammation and oxidative stress, while two will investigate ways to target the Parkinson's-implicated protein alpha-synuclein (including FoldRx Pharmaceuticals' continuing investigation of small-molecule drug candidates to inhibit alpha-synuclein toxicity, funded by MJFF since 2007). The remaining team will investigate HDACs, a family of enzymes that have been shown to enhance expression of potential protective factors in preclinical models of PD and may also regulate clearance of toxic proteins.

While MJFF welcomes applications from industry researchers under all of its programs, TDI -- first launched in 2006 -- is the Foundation's only industry-exclusive funding stream. It is a key element of MJFF's strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.

Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available in the Searchable Database of Funded Grants at www.michaeljfox.org/research. As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Projects Focused on Inflammation and Oxidative Stress

Design of Neuroprotective Drugs to Reduce Oxidative Damage and Alpha-Synuclein Toxicity in Parkinson's Disease

Stig Hansen, Ph.D., Carmot Therapeutics, Inc.

Targeting TLR2 as a Novel Therapy for Parkinson's Disease

Andrew Parker, Ph.D., Opsona Therapeutics LTD

An Innovative Drug for Disease-Modifying Treatment of Parkinson's Disease

Philipp Wabnitz, Ph.D., InterMed Discovery GmbH

Projects Focused on Alpha-Synuclein

Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinson's Disease

Christine Bulawa, Ph.D., FoldRx Pharmaceuticals, Inc.

Developing Autophagy Enhancers as Disease-modifying Therapeutics for Parkinson's Disease

John Dunlop, Ph.D., Pfizer Global Research and Development

HDACs

Potential Efficacy of a Novel, Orally Bioavailable, CNS-penetrant HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease

Holger Patzke, Ph.D., Envivo Pharmaceuticals

TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $18.6 million total for 39 industry-led projects under the initiative.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. To date, the Foundation has funded almost $170 million in research. For more information on TDI and the Foundation's industry strategy, please visit www.michaeljfox.org/industry.

SOURCE Michael J. Fox Foundation

RELATED LINKS
http://www.michaeljfox.org

'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
2. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
3. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
4. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
5. Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinsons Disease Hits Major Milestone
6. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 2010
7. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
8. Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinsons Therapeutic Targets
9. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
10. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
11. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 ... company specializing in the development of innovative peptide ... and metastatic disease, today announced that it will ... Dr. Glynn Wilson , Chairman ... of the company,s business, clinical pipeline and partnering ...
(Date:3/22/2017)... March 22, 2017 Hologic, Inc. (Nasdaq: ... the acquisition of Cynosure, Inc., a leader in medical ... cash. "We are pleased to complete our ... Michael Davin and the entire Cynosure team ... growing medical aesthetics market," said Steve MacMillan , ...
(Date:3/22/2017)... TFS is pleased to announce the appointment ... , two global executive positions in Medical Affairs and Clinical Development. ... Team and will report to Dr. Montse Barceló , Chief ... ... years of medical and scientific expertise gained across leading biopharmaceutical companies ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 2017 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had won the ‘Clinical Supply Chain Excellence’ category ... International Exhibition & Convention Centre, Singapore. The award was presented at the conference ...
(Date:3/22/2017)... ... 2017 , ... Old School Labs™, makers of the best-selling Vintage line of ... Ambassador. Theophane, who trained with Floyd Mayweather, made his professional debut in London in ... an impressive number of wins in contests in Britain, Germany and the U.S. ...
(Date:3/22/2017)... ... March 22, 2017 , ... Wash Tower Ltd. has released a series of ... Tower, the world's first standalone constant pressure bidet. , The videos in the series ... https://www.washtower.com as well as on its social media pages. , Each video ...
(Date:3/22/2017)... SC (PRWEB) , ... March 22, 2017 , ... Drs. ... expanding their patient base to accept new patients in need of skilled pediatric ... experience, India Hook Dental Care offers pediatric patients routine treatments, including cavities, sealants and ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, ... clinical trial for the treatment of non-small cell lung cancer and small cell ...
Breaking Medicine News(10 mins):